July 6, 2021 09:56 AM EDTUpdated July 7, 07:15 AM
R&D
Pharma

Eli Lil­ly, Boehringer In­gel­heim tout piv­otal heart fail­ure win for Jar­diance, po­ten­tial­ly set­ting up a No­var­tis show­down

Kyle Blankenship

The ma­jor mar­ket for chron­ic heart fail­ure — un­til re­cent­ly an in­di­ca­tion with­out a sin­gle ap­proved ther­a­py — has evolved in­to a horse race in re­cent months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times